Skip to main content
Clinical Trials/CTRI/2018/05/013754
CTRI/2018/05/013754
Recruiting
未知

A Retrospective Safety Data Collection Registry of VivitraTM (Trastuzumab) - VivitraTM Registry

Cadila Healthcare Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- 1. Metastatic breast cancer2. Metastatic Gastric Cancer3. Early Breast Cancer
Sponsor
Cadila Healthcare Ltd
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patient should have completed the 4 cycle of VivitraTM treatment on the approved indications

Exclusion Criteria

  • Any reason which may prevent the doctor to enroll the patient in the registry.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2009-017978-21-DEMerck Serono S.A. - Geneva1,148
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 14.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2009-017978-21-ITMERCK SERONO SA1,148
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials
EUCTR2009-017978-21-EEMerck Serono S.A. - Geneva2,175
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials
EUCTR2009-017978-21-BEMerck Serono S.A. - Geneva1,148
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials
EUCTR2009-017978-21-LVMerck Serono S.A. - Geneva2,175